Interações medicamentosas
Buprenorphine + Tranylcypromine
Gravidade: Contraindicada
Buprenorphine and Tranylcypromine: contraindicated interaction.
Última atualização
Para profissionais de saúde — apenas referência. Esta página é um resumo breve, não é aconselhamento médico nem substitui a bula oficial ou o julgamento clínico. Verifique sempre antes de prescrever ou dispensar.
O conteúdo clínico desta página está disponível apenas em inglês.
Resumo
Combining opioids with a nonselective MAO inhibitor has caused severe reactions such as hypotension, hyperthermia, profound sedation, serotonin toxicity and death. Buprenorphine labeling advises against use during or within 14 days of MAOI treatment.
O que esta interação significa em palavras simples
Buprenorphine and Tranylcypromine are not normally used together. Taking them at the same time is expected to cause harm or make one of them unsafe, so a different medicine is usually chosen for one of the two.
Buprenorphine belongs to Musculoskeletal; Tranylcypromine belongs to Central Nervous System.
Por que acontece
MAO inhibition may potentiate serotonergic and CNS-depressant effects of opioids; the exact mechanism with buprenorphine is not fully defined.
O que fazer
Do not use together; separate by at least 14 days after stopping tranylcypromine and choose a non-interacting analgesic.
O que perguntar ao farmacêutico
- Is there an alternative to one of these two medicines for me?
- If both are essential, who is monitoring me and how often?
- Which symptoms mean I should stop and seek help straight away?
Para assinantes do Pro+
Desbloqueie a página completa
Crie uma conta e comece um teste do Pro+ para desbloquear a orientação completa de conduta para Buprenorphine e Tranylcypromine, as notas adicionais, os detalhes da evidência e o verificador de interações para uma prescrição completa.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Experimente o Pro+ grátis por 14 dias na web. Sem cartão.
Outras interações de Buprenorphine
- Alvimopan + Buprenorphine Contraindicada
- Buprenorphine + Calcium / magnesium / potassium / sodium oxybates Contraindicada
- Buprenorphine + Olanzapine / samidorphan Contraindicada
- Buprenorphine + Phenelzine Contraindicada
- Buprenorphine + Pimozide Contraindicada
- Buprenorphine + Thioridazine Contraindicada
Outras interações de Tranylcypromine
- 5-HTP + Tranylcypromine Contraindicada
- Amitriptyline + Tranylcypromine Contraindicada
- Amoxapine + Tranylcypromine Contraindicada
- Atomoxetine + Tranylcypromine Contraindicada
- Benzphetamine + Tranylcypromine Contraindicada
- Brimonidine + Tranylcypromine Contraindicada
Perguntas frequentes
Can I take Buprenorphine with Tranylcypromine?
MediHelp rates the interaction as contraindicated. Buprenorphine and Tranylcypromine are not normally used together. Taking them at the same time is expected to cause harm or make one of them unsafe, so a different medicine is usually chosen for one of the two. Combining opioids with a nonselective MAO inhibitor has caused severe reactions such as hypotension, hyperthermia, profound sedation, serotonin toxicity and death. Buprenorphine labeling advises against use during or within 14 days of MAOI treatment.
How serious is the interaction between Buprenorphine and Tranylcypromine?
MediHelp rates it contraindicated, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Do not use together; separate by at least 14 days after stopping tranylcypromine and choose a non-interacting analgesic.
What other medicines interact with Buprenorphine?
MediHelp also lists interactions of Buprenorphine with, for example, Alvimopan, Calcium / magnesium / potassium / sodium oxybates, Olanzapine / samidorphan. The full list is on the Buprenorphine page.
Monografias completas, posologia e verificador de interações no app MediHelp
Abra a referência completa, verifique interações entre vários medicamentos e use as ferramentas de posologia no app MediHelp.
